[vc_row][vc_column width="1/4"][vc_single_image image="19304" img_size="medium" alignment="center" css=""][/vc_column][vc_column width="3/4"][vc_column_text css=""]Although stomach cancer, also known as gastric cancer, is the third deadliest cancer in the world, claiming an estimated 10,960 lives in the United States alone in 2017, it remains one of the more difficult cancers to notice...
FOR IMMEDIATE RELEASE: February 15, 2018 CONTACT: Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@nfcr.org First Occasion for Award to Recognize Extraordinary Contributions in Cancer Prevention, Role of Vaccines BETHESDA, MD - The National Foundation for Cancer Research (NFCR) announced today that the 2018 Szent-Györgyi Prize for Progress...
[vc_row][vc_column][vc_column_text css=""]CLEVELAND, OH — Two studies conducted by the Cleveland Clinic revealed how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this...
Scientists at Bar-Ilan University in Israel successfully targeted and rendered inert the enzyme that metastatic cancer cells need to survive in the body once they have left their host tumor. ...
Szent-Györgyi Prize Winners: Then & Now The Szent-Györgyi Prize was established in honor of Nobel laureate Dr. Albert Szent-Györgyi, co-founder of NFCR, to recognize outstanding scientific achievement in the war against cancer. Ten years later, “ASG Winners: Then & Now” looks at these winners, their extraordinary contributions and how their discoveries...
[vc_row][vc_column][vc_column_text css=""]Cancer May Metastasize Without Lymph Node Involvement NFCR-funded research finds two distinct patterns of metastatic spread in human colorectal cancer (Bethesda, MD, July 13, 2017) Research by several leading scientists including Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the...
Just last week, the U.S. Food and Drug Administration approved the cancer medicine— Keytruda® (generic name pembrolizumab)— to treat cancers that have a specific genetic mutation or biomarker. This is the first time a cancer treatment has been approved based on a biomarker rather than...
Targeting HER3 could cripple metastatic cancers that have spread to the brain. (Bethesda, MD, June 5, 2017) Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has...
A liquid biopsy can provide valuable insight into how to best fight cancer. This noninvasive diagnostic is particularly helpful for patients who cannot undergo a surgical biopsy or whose tumor sample has been exhausted. In the not-too-distant future, liquid biopsies may be used to guide...
[vc_row][vc_column width="1/3"][vc_empty_space height="22px"][vc_single_image image="14199" img_size="large" alignment="center" css=""][/vc_column][vc_column width="2/3"][vc_column_text css=""] What is “genomics”? Cancer develops when genetic material (DNA) becomes damaged or changed. We know some cancer-causing genetic changes are acquired (e.g., smoking), while others are inherited. Studying cancer genomics explores the differences between cancer cells and normal...
Search NFCR
Popular searches